Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash & Equivalents (2022 - 2025)

Taysha Gene Therapies' Cash & Equivalents history spans 4 years, with the latest figure at $312.8 million for Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 81.06% year-over-year to $312.8 million; the TTM value through Jun 2025 reached $312.8 million, up 81.06%, while the annual FY2024 figure was $139.0 million, 2.36% down from the prior year.
  • Cash & Equivalents for Q2 2025 was $312.8 million at Taysha Gene Therapies, up from $116.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $312.8 million in Q2 2025 and bottomed at $36.9 million in Q3 2022.
  • The 4-year median for Cash & Equivalents is $124.0 million (2024), against an average of $126.2 million.
  • The largest YoY upside for Cash & Equivalents was 344.68% in 2023 against a maximum downside of 34.54% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $36.9 million in 2022, then skyrocketed by 285.46% to $142.4 million in 2023, then decreased by 2.36% to $139.0 million in 2024, then surged by 124.95% to $312.8 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Cash & Equivalents are $312.8 million (Q2 2025), $116.6 million (Q1 2025), and $139.0 million (Q4 2024).